Video: Oncimmune Scientists Decode Autoantibody Reactome Using xMAP® Technology

18 April 2024

At Oncimmune, scientists have developed one of the largest commercially available antigen libraries—spanning over 9,000 antigens and covering more than 95% of human antigens. As a precision medicine company specializing in examining immune interactions through the autoantibody profile, it is thanks to their ImmunoINSIGHTSTM platform that Oncimmune discovers and converts autoantibodies into actionable biomarkers, offering applications across immuno-oncology, autoimmune diseases, metabolic disorders, and neuroscience.

Moreover, Oncimmune enables biotech, biopharma, and contract research organizations (CROs) to harness these autoantibody biomarkers for early-stage discovery, mechanism of action validation, patient stratification in clinical trials, and for predicting treatment response or adverse events. In addition, the technology may also be used for discovering “clinically silent” autoantibodies for early disease detection.

Analyze thousands of antigens across thousands of samples using xMAP® Technology

The company has demonstrated success in profiling autoimmune signatures of patients for eight of the top 15 global pharma companies for de-risking key assets.

To maximize high-throughput studies, the Oncimmune team utilizes xMAP Technology. This approach allows them to analyze thousands of antigens across hundreds or thousands of samples using low sample volume (less than 50 μl).

In the Oncimmune partner spotlight video, the world-class scientific team introduces their impressive facility and discusses how xMAP Technology has positively impacted their work.

Published on Diasorin website by Luminex. [LINK]